$IONS
IONIS PHARMACEUTICALS INC

2021 Q3 Form 10-Q Financial Statement

#000087401521000166 Filed on November 03, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2020 Q3
Revenue $133.1M $160.1M
YoY Change -16.87% -4.64%
Cost Of Revenue $3.079M $3.100M
YoY Change -0.68% 210.0%
Gross Profit $130.0M $157.0M
YoY Change -17.19% -5.93%
Gross Profit Margin 97.69% 98.06%
Selling, General & Admin $31.09M $68.40M
YoY Change -54.54% 14.0%
% of Gross Profit 23.92% 43.57%
Research & Development $184.8M $125.1M
YoY Change 47.7% 19.83%
% of Gross Profit 142.12% 79.68%
Depreciation & Amortization $4.317M $3.800M
YoY Change 13.61% 18.75%
% of Gross Profit 3.32% 2.42%
Operating Expenses $215.9M $193.5M
YoY Change 11.56% 17.7%
Operating Profit -$85.85M -$36.50M
YoY Change 135.2% -1546.69%
Interest Expense $2.545M $2.428M
YoY Change 4.82% 120.73%
% of Operating Profit
Other Income/Expense, Net -$469.0K $100.0K
YoY Change -569.0% -200.0%
Pretax Income -$83.77M -$31.55M
YoY Change 165.52% -1001.43%
Income Tax -$1.307M $5.064M
% Of Pretax Income
Net Earnings -$82.47M -$24.47M
YoY Change 237.05% -193.52%
Net Earnings / Revenue -61.96% -15.28%
Basic Earnings Per Share -$0.58 -$0.18
Diluted Earnings Per Share -$0.58 -$0.18
COMMON SHARES
Basic Shares Outstanding 141.1M 139.7M
Diluted Shares Outstanding 141.1M 139.7M

Balance Sheet

Concept 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.987B $2.329B
YoY Change -14.69% 4.88%
Cash & Equivalents $633.0M $633.1M
Short-Term Investments $1.354B $1.696B
Other Short-Term Assets $136.6M $146.6M
YoY Change -6.79% 23.4%
Inventory $22.93M $22.20M
Prepaid Expenses
Receivables $9.068M $39.00M
Other Receivables $0.00 $0.00
Total Short-Term Assets $2.156B $2.537B
YoY Change -15.03% 5.35%
LONG-TERM ASSETS
Property, Plant & Equipment $180.1M $181.5M
YoY Change -0.75% 12.24%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $48.97M $348.9M
YoY Change -85.96% 17.0%
Total Long-Term Assets $259.2M $558.7M
YoY Change -53.61% 14.75%
TOTAL ASSETS
Total Short-Term Assets $2.156B $2.537B
Total Long-Term Assets $259.2M $558.7M
Total Assets $2.415B $3.096B
YoY Change -21.99% 6.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.357M $16.20M
YoY Change -48.41% 23.66%
Accrued Expenses $108.0M $109.1M
YoY Change -1.01% 37.93%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $65.05M $5.800M
YoY Change 1021.47%
Total Short-Term Liabilities $279.8M $244.6M
YoY Change 14.38% 5.52%
LONG-TERM LIABILITIES
Long-Term Debt $1.242B $814.8M
YoY Change 52.39% 24.07%
Other Long-Term Liabilities $362.9M $429.9M
YoY Change -15.59% -15.47%
Total Long-Term Liabilities $1.605B $1.245B
YoY Change 28.91% 6.81%
TOTAL LIABILITIES
Total Short-Term Liabilities $279.8M $244.6M
Total Long-Term Liabilities $1.605B $1.245B
Total Liabilities $1.884B $1.713B
YoY Change 10.03% 9.87%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $530.5M $1.383B
YoY Change
Total Liabilities & Shareholders Equity $2.415B $3.096B
YoY Change -21.99% 6.93%

Cashflow Statement

Concept 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$82.47M -$24.47M
YoY Change 237.05% -193.52%
Depreciation, Depletion And Amortization $4.317M $3.800M
YoY Change 13.61% 18.75%
Cash From Operating Activities -$55.57M -$10.40M
YoY Change 434.37% -18.75%
INVESTING ACTIVITIES
Capital Expenditures -$3.323M -$11.80M
YoY Change -71.84% -25.79%
Acquisitions
YoY Change
Other Investing Activities $125.3M $113.7M
YoY Change 10.2% 557.23%
Cash From Investing Activities $122.0M $101.9M
YoY Change 19.7% 7178.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.458M 11.00M
YoY Change -86.75% -183.33%
NET CHANGE
Cash From Operating Activities -55.57M -10.40M
Cash From Investing Activities 122.0M 101.9M
Cash From Financing Activities 1.458M 11.00M
Net Change In Cash 67.86M 102.5M
YoY Change -33.8% -516.67%
FREE CASH FLOW
Cash From Operating Activities -$55.57M -$10.40M
Capital Expenditures -$3.323M -$11.80M
Free Cash Flow -$52.25M $1.400M
YoY Change -3832.21% -54.84%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0000874015
dei Security12b Title
Security12bTitle
Common Stock, $.001 Par Value
dei Trading Symbol
TradingSymbol
IONS
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-19125
dei Entity Registrant Name
EntityRegistrantName
Ionis Pharmaceuticals, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
33-0336973
dei Entity Address Address Line1
EntityAddressAddressLine1
2855 Gazelle Court
dei Entity Address City Or Town
EntityAddressCityOrTown
Carlsbad
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92010
dei City Area Code
CityAreaCode
760
dei Local Phone Number
LocalPhoneNumber
931-9200
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
141210015
CY2021Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2020Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-8627000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2021Q3 ions Number Of Publicly Traded Companies In Which Entity Has Equity Investment Included In Other Current Assets
NumberOfPubliclyTradedCompaniesInWhichEntityHasEquityInvestmentIncludedInOtherCurrentAssets
2
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-83773000
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-31550000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-254064000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-119979000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.80
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.64
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
141139000
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
139708000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
140958000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
139497000
us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
90550000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
89752000
us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
-136620000
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.58
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18
us-gaap Payments To Acquire Equity Securities Fv Ni
PaymentsToAcquireEquitySecuritiesFvNi
7185000
us-gaap Payments To Acquire Equity Securities Fv Ni
PaymentsToAcquireEquitySecuritiesFvNi
0
us-gaap Payments Of Merger Related Costs Financing Activities
PaymentsOfMergerRelatedCostsFinancingActivities
0
us-gaap Payments Of Merger Related Costs Financing Activities
PaymentsOfMergerRelatedCostsFinancingActivities
1071000
ions Acquisition Transaction Costs Incurred But Not Yet Paid
AcquisitionTransactionCostsIncurredButNotYetPaid
0
ions Acquisition Transaction Costs Incurred But Not Yet Paid
AcquisitionTransactionCostsIncurredButNotYetPaid
8103000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-8627000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
632500000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
15525000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
256963000
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
0
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
89752000
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
0
us-gaap Payments For Hedge Financing Activities
PaymentsForHedgeFinancingActivities
136620000
us-gaap Payments For Hedge Financing Activities
PaymentsForHedgeFinancingActivities
0
CY2021Q3 ions Debt Instrument Number Of Convertible Notes
DebtInstrumentNumberOfConvertibleNotes
2
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5064000
CY2020Q3 us-gaap Profit Loss
ProfitLoss
-36614000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-24467000
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
743282000
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1577458000
CY2020Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
308809000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1895519000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1131306000
CY2020Q3 us-gaap Interest Expense
InterestExpense
2428000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.80
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-31550000
us-gaap Interest Expense
InterestExpense
7076000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-119979000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4077000
us-gaap Profit Loss
ProfitLoss
-124056000
us-gaap Net Income Loss
NetIncomeLoss
-89731000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.64
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.64
CY2021Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
616
CY2021Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
647954000
CY2021Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
865000

Files In Submission

Name View Source Status
0000874015-21-000166-index-headers.html Edgar Link pending
0000874015-21-000166-index.html Edgar Link pending
0000874015-21-000166.txt Edgar Link pending
0000874015-21-000166-xbrl.zip Edgar Link pending
ex10-1.htm Edgar Link pending
ex10-2.htm Edgar Link pending
ex31_1.htm Edgar Link pending
ex31_2.htm Edgar Link pending
ex32_1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
form10q.htm Edgar Link pending
form10q_htm.xml Edgar Link completed
image1.jpg Edgar Link pending
image2.jpg Edgar Link pending
ions-20210930.xsd Edgar Link pending
ions-20210930_cal.xml Edgar Link unprocessable
ions-20210930_def.xml Edgar Link unprocessable
ions-20210930_lab.xml Edgar Link unprocessable
ions-20210930_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending